Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

4
Player Avatar zzlangerhans (99.85) Submitted: 1/10/2013 8:17:46 PM : Underperform Start Price: $1.36 PPHM Score: +12.30

The other day I saw one of the nurses with a new hairstyle. I thought I'd be funny so I told her she looked different that day? "Didn't you use to have a mustache?" I asked her. She gave me a weird look and scurried away. Later I found out she'd had her upper lip waxed too.

Now that's embarrassing. But not half as embarrassing as red thumbing Peregrine one day before they came out with positive PR on their withdrawn OS data from the phase II bavituximab lung cancer trial. In retrospect, I realized I was so eager to regain score leadership on Peregrine that I was ignoring the substantial likelihood of a PR like this one. A stock like this is just too juicy for mono traders to stay in the pennies.

I'm still confident that bavituximab is inert, for the same reasons I had before the bogus OS data was released in the first place. But Peregrine won't die easily and now I may have to wait months before getting another chance to play.

Report this Post 2 Replies
Member Avatar Momentum21 (44.33) Submitted: 1/11/2013 1:39:13 PM
Recs: 0

Did she happen to smell like Honey Nut Cheerios?

Member Avatar alvojiggy (87.26) Submitted: 2/8/2013 12:40:15 AM
Recs: 0

On a brighter note... at least you learned what pick up line not to use next time. ;)

Featured Broker Partners


Advertisement